6-Halo-1,2,3,4-tetrahydr oquinazoline-4-spiro-4-imidazolidine-2,2'5'-triones useful for the treatment and prophylaxis of diabetic complications

• US 4,855,298 A
• Filed: 10/29/1987
• Issued: 08/08/1989
• Est. Priority Date: 11/21/1986
• Status: Expired due to Fees

• Current Assignee: Tanabe Seiyaku Co Ltd (Mitsubishi Chemical Group Corp.)
• Original Assignee: Tanabe Seiyaku Co Ltd (Mitsubishi Chemical Group Corp.)
• Inventors: Yamada, Yoshihisa, Matsuoka, Yuzo
• Primary Examiner(s): Sutto, Anton H.
• Assistant Examiner(s): BERNHARDT, EMILY A
• Application Number:
  US07/114,569
• Time in Patent Office: 649 Days
• Field of Search: 514/259, 544/230, 544/231, 544/286
• US Class Current: 514/267
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07C 275/50 Y being a hydrogen or an acyclic carbon atom
• CPC Class Codes: C07D 487/10 Spiro-condensed systems

Abstract

A quinazolinone derivative of the formula: ##STR1## wherein R¹ is hydrogen atom or a halogen atom, or a salt thereof and processes for preparing the same are disclosed. The quinazolinone derivative (I) is useful for treatment of diabetic complications.

Claims

1. A quinazolinone compound of the formula:

##STR8## wherein R¹ is a halogen atom, or a non-toxic pharmaceutically acceptable salt thereof.

2. The compound claimed in claim 1 which is 6-chloro-1,2,3,4-tetrahydroquinazoline-4-spiro-4'"'"'-imidazolidine-2,2'"'"',5'"'"'-trione or a non-toxic pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 in which halo is fluoro, chloro, or bromo.

4. A pharmaceutical composition which comprises a therapeutically effective amount of the compound according to claim 1 and a pharmaceutically acceptable carrier therefor.

5. The composition according to claim 4 in which the compound is 6-chloro-1,2,3,4-tetrahydroquinazoline-4-spiro-4'"'"'-imidazolidine-2,2'"'"',5'"'"'-trione or a non-toxic pharmaceutically acceptable salt thereof.

6. A method for the treatent of diabetic complications in a warm-blooded animal which comprises administering to said warm-blooded animal an anti-diabetic effective amount of the compound according to claim 1.

7. The method according to claim 6 wherein the compound is 6-chloro-1,2,3,4-tetrahydroquinazoline-4-spiro-4'"'"'-imidazolidine-2,2'"'"',5'"'"'-trione or a non-toxic pharmaceutically acceptable salt thereof.